CASI Pharmaceuticals FY2023 GAAP EPS $(2.02) Misses $(1.93) Estimate, Sales $33.88M Miss $36.42M Estimate
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals reported FY2023 GAAP EPS of $(2.02), missing the $(1.93) estimate, and sales of $33.88M, missing the $36.42M estimate. This represents a 32.89% increase in losses per share and a 21.41% decrease in sales from the same period last year.
March 28, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
CASI Pharmaceuticals reported a larger than expected quarterly loss and a miss in sales estimates for FY2023.
CASI Pharmaceuticals' reported earnings and sales were both below analyst expectations, indicating potential operational challenges or market conditions affecting its performance. The miss in both EPS and sales estimates is likely to negatively impact investor sentiment in the short term, leading to a potential decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100